Revenue, market share and growth are the challenges facing life science companies. Mergers, acquisitions, joint ventures, divestitures, and licensing are impacting the sector as expiring patents, shorter product life cycles, formulary coverage challenges, and value-based reimbursements are forcing companies to look at new strategies and alter business models.
Health reform and a drive for value are causing a shift from volume- to value-based care. This creates the need for the industry to demonstrate and communicate the true value of drug and device prices, with an emphasis on a product’s clinical safety and commercial impact.
The risks related to medical ethics, product safety, security and privacy concerns, and intellectual property disputes, are impacting companies. As governments are tightening regulations to address these risks, there is a greater call for transparency among both the healthcare industry and Life Science companies. Just as HCP compliance has become a critical focus, so too, has the need to better articulate value proposition and use real-world evidence to demonstrate a product’s effectiveness.
At Creative Group we understand the importance of helping companies employ proactive risk management and adhere to regulatory compliance. Whether for product launches or customer-based meetings, we are experts at driving to corporate initiatives for success, as well as managing to HCP guidelines, with flawless execution for meetings and events.
Work with us to leverage our life sciences expertise.